The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID‐19: A meta‐analysis of randomized trialsCOVID-19 환자의 사망률 및 입원 기간에 대한 콜히친의 영향: 무작위 시험의 메타 분석Meta-Analysis Published on 2021-12-302022-09-10 Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), MERS, SARS, 임상, [키워드] 95% CI 95% confidence interval aims appear benefit Clinical deterioration clinical trial registries clinical trial registry Colchicine coronavirus coronavirus disease COVID‐19 database domain Effect eligible Hospital stay hospitalized patient hospitalized patients Inflammasome inhibitor lead material Mortality NLR NLRP3 NLRP3 inflammasome NLRP3 inhibitor no significant difference Odds ratio outcome overactivation Patient Potential treatment Prevent randomized trial randomized trials reduce reduction in Result SARS-CoV-2 searched standardized mean difference systematic review translate Treatment was used [DOI] 10.1002/iid3.562 PMC 바로가기 [Article Type] Meta-Analysis
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19 A Randomized Clinical TrialCOVID-19 A 무작위 임상 시험으로 입원한 환자의 삽관 및 28일 사망률에 대한 콜히친 대 일반 치료 단독의 효과Randomized Controlled Trial Published on 2021-12-292022-09-12 Journal: JAMA Network Open [Category] SARS, 임상, 진단, 치료법, [키워드] 1:1 28-day mortality 95% CI acute respiratory syndrome Administered adverse effect age analyzed assigned Chain Reaction Chronic kidney disease clinical clinical trial Colchicine colchicine group Composite contraindication contraindications Corticosteroids COVID-19 COVID-19 pneumonia COVID-19 symptoms death demonstrated Desaturation diarrhea discharge dose ECLA Effect Efficacy evaluated exclusion criteria finding followed by hazard ratio Hospitalized hospitalized patient hospitalized patients Importance indication initial intubation Kidney disease Latino Loading dose measure mechanical ventilation men morbidity morbidity and mortality Mortality multicenter no significant difference objective occurred Open-label outcome oxygen participant Patient patients hospitalized patients with COVID-19 performed Pneumonia Point Population Prevent randomization Randomized randomized clinical trial receive reduce Registration Relevance reported Result SARS-CoV-2 SARS-COV-2 infection setting Severe acute respiratory syndrome significantly Symptom Trial twice a day usual care usual care alone usual care group were used with COVID-19 women [DOI] 10.1001/jamanetworkopen.2021.41328 PMC 바로가기 [Article Type] Randomized Controlled Trial
Colchicine use in patients with COVID-19: A systematic review and meta-analysisCovid-19 환자의 콜히친 사용 : 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-12-282022-09-10 Journal: PLoS ONE [Category] SARS, 유전자 메커니즘, 치료제, [키워드] 95% CI Admissions analyzed Care Clinical outcome Colchicine COVID-19 COVID-19 patient COVID-19 pneumonia Cytokines determine Efficacy hazard ratio ICU ICU admission ICU admissions identify individuals with COVID-19 inflammasome signaling inhibit intensive care intensive care unit Long-term care lower risk mechanical ventilation mechanism Meta-analysis Mortality no statistical difference Odds ratio outcome Patient patients patients with COVID-19 Pneumonia proinflammatory cytokines RCT RECOVERY trial reduce reference reported Result risk risk ratio screened searched systematic review the disease Treatment Trial [DOI] 10.1371/journal.pone.0261358 PMC 바로가기 [Article Type] Meta-Analysis
Acute Pericarditis Secondary to COVID-19 InfectionCardiology Published on 2021-12-262022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome cardiac injury caused Colchicine Complication coronavirus Coronavirus disease 2019 covid pericarditis COVID-19 COVID-19 infection discharged effective High-dose Hospitalized Infection NSAIDS pandemic Patient Pericarditis recurrent pericarditis SARS-CoV-2 secondary to the patient transthoracic echocardiography (tte) treated Treatment [DOI] 10.7759/cureus.20709 PMC 바로가기 [Article Type] Cardiology
Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking AnalysisReview Published on 2021-12-232022-10-30 Journal: Medicina [Category] COVID-19, SARS, [키워드] Ability addition Analysis Anti-inflammatory anti-inflammatory activity antiviral activity ASN142 binding boceprevir Colchicine complex complexes Coronavirus disease 2019 COVID-19 COVID-19 cytokine storm Cys145 Cytokine storm docking Donor enzyme Evidence global pandemic Glu166 Gly143 hallmark Health hydrogen bonds hydrophobic interaction improve clinical outcomes indicated inhibiting Interaction life threatening management manifestation manifested Mild symptom molecular docking Pathways Potential pro-inflammatory cytokine Probability protease Protease inhibitor provided RdRP reduce respiratory RNA polymerase RNA-dependent RNA polymerase role SARS-CoV-2 Seven severity stability storm the cytokine storm the disease [DOI] 10.3390/medicina58010020 PMC 바로가기 [Article Type] Review
Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trialResearch article Published on 2021-12-202022-10-05 Journal: EClinicalMedicine [Category] 임상, [키워드] 28-day mortality 95% CI age all-cause mortality Analysis assigned candidate Colchicine Combination combined use conducted Consensus contraindication Corticosteroid COVID-19 determine diagnosis of COVID-19 diarrhoea dose drug Effectiveness enrolled Exanthema finding fumarate hazard ratio hospital hospitalized patient Invasive mechanical ventilation medications modified intention-to-treat multicentre Open-label Patient patients Pneumonia Pragmatic primary endpoint Randomized Randomized controlled trial randomized trial reduce reduce mortality Registered risk SARS-CoV-2 disease SARS-COV-2 infection severe adverse events shown significantly lower Standard of care Treatment Trial was used [DOI] 10.1016/j.eclinm.2021.101242 [Article Type] Research article
The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline코로나19 입원환자 사망률에 대한 치료제의 영향: 유럽호흡기학회 생활지침을 알려주는 체계적인 검토 및 메타분석Review Published on 2021-12-152022-09-11 Journal: European respiratory review : an official journal [Category] SARS, 치료제, [키워드] anti-IL-6 receptor Anti-inflammatory Anti-viral Azithromycin Colchicine comparator conducted coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 Dexamethasone Effect estimate European Evidence guideline high mortality rate hospitalised patient Hospitalised patients Hydroxychloroquine identify inclusion criteria interferon International Intervention Lopinavir Lopinavir/ritonavir Meta-analysis monoclonal antibodies monoclonal antibody monoclonal antibody therapy Mortality other treatments outcome Patient question Random-effects meta-analysis randomised controlled trial Randomised controlled trials recommendation Remdesivir respiratory Ritonavir Society Support systematic review systematic reviews therapy These data Treatment use of corticosteroids was used with COVID-19 [DOI] 10.1183/16000617.0171-2021 PMC 바로가기 [Article Type] Review
Antirheumatic Drugs against COVID-19 from the Perspective of RheumatologistsReview Published on 2021-12-022022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] activate anti-IL-1 Antigen antirheumatic Antirheumatic drugs Baricitinib blockade Chloroquine clinical impact Colchicine Coronavirus disease 2019 Course COVID-19 cytokine Cytokine storm Disease progression Diseases drug drugs effective expected Glucocorticoids Hydroxychloroquine Immune cell immunomodulatory immunosuppressants immunosuppressive drug Immunosuppressive treatment Inflammatory cytokines inhibitor inhibitors Janus kinase inhibitor management mechanism mechanism of action Necrosis pandemic Pathogenesis pathophysiology patient death prevent disease progression Rheumatic diseases sarilumab SARS-CoV-2 Stage the cytokine storm the disease Tocilizumab Tofacitinib treatment for COVID-19 viral replication [DOI] 10.3390/ph14121256 PMC 바로가기 [Article Type] Review
Host-modifying drugs against COVID-19: some successes, but not yet the breakthroughCOVID-19에 대한 숙주 변형 약물: 일부 성공, 그러나 아직 돌파구 없음Review Published on 2021-12-012022-09-11 Journal: Environmental microbiology [Category] meta-analysis, SARS, 임상, 치료제, [키워드] Anakinra anti-inflammatory treatment antibiotic anticoagulation antiviral drug antiviral drugs Azithromycin Baricitinib benefit clinical clinical benefit clinical benefits clinical trial clinical trials Colchicine Corticosteroid COVID-19 patients criteria demonstrated Dexamethasone drug Effect hospitalized patient hospitalized patients hyperinflammation immunomodulators immunomodulatory activity Infection inferiority inhibitor interleukin 6 interleukin 6 receptor Janus kinase Kinase inhibitor Meta-analysis Microbiology Mortality no effect no effects outcome oxygen pathology Patient receptor receptor antagonist reducing Repurposed drug Repurposed drugs SARS-CoV-2 virus severe cases stages subgroups of patient supplementary oxygen survival the SARS-CoV-2 virus therapeutic dose Tocilizumab Treatment Trial Ventilation [DOI] 10.1111/1462-2920.15828 PMC 바로가기 [Article Type] Review
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialCovid-19 (회복)로 병원에 입원 한 환자의 콜히친 : 무작위, 통제, 오픈 라벨, 플랫폼 시험Randomized Controlled Trial Published on 2021-12-012022-08-13 Journal: The Lancet. Respiratory Medicine [Category] MERS, SARS, 임상, [키워드] (Medical Research Council) 1:1 28-day mortality allocation concealment Analysis anti-inflammatory actions assigned baseline both groups by mouth clinically suspected clinician Colchicine colchicine 1 mg colchicine group composite endpoint CYP3A4 CYP3A4 inhibitor death died Diltiazem discharge discharged Efficacy and safety eligible enrolled estimated glomerular filtration rate evaluate filtration rate finding followed by for inclusion Frequency funding glomerular filtration rate had no hospital Hospital stay hospitalised hospitals in Indonesia hospitals in Nepal in both groups Indonesia Innovation Intention intention-to-treat Invasive mechanical ventilation ISRCTN Laboratory less medical history Medical Research Council moderate nasogastric tube Nepal no significant difference Open-label open-label trial opinion participant Patient Platform trial Primary outcome proportion randomisation randomised Randomly rate ratio receive receiving RECOVERY trial reductions reductions in Registered risk risk ratio SARS-COV-2 infection secondary endpoint Secondary endpoints significant difference Standard of care subgroups of patients the patient Treatment treatment for COVID-19 Trial twice a day usual care usual care group web-based simple Wellcome Trust with COVID-19 [DOI] 10.1016/S2213-2600(21)00435-5 PMC 바로가기 [Article Type] Randomized Controlled Trial